MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Income Overview

Revenue
$13,819K
Net Income
-$22,864K
Net Profit Margin
-165.45%
EPS
-$0.18
Unit: Thousand (K) dollars
Revenue Breakdown
    • Manufacture And Supply Revenue
    • License And Royalty Revenue
    • Co Development And Research Fees
Revenue Breakdown
    • US
    • Non Us
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenues
13,819
14,446
13,015
12,807
Manufacture and supply
4,017
3,469
5,836
4,506
Research and development
3,962
4,204
3,196
4,530
Selling, general and administrative
14,063
10,977
32,822
15,250
Total costs and expenses
22,042
18,650
41,854
24,286
Loss from operations
-8,223
-4,204
-28,839
-11,479
Loss on extinguishment of debt
-11,683
-
-
-
Interest expense
2,807
2,903
2,778
2,779
Interest expense related to royalty obligations
972
973
1,433
1,433
Interest expense related to the sale of future revenue
61
60
62
61
Interest income and other income, net
882
83
1,252
306
Net loss before income taxes
-22,864
-8,057
-31,860
-15,446
Income taxes benefit
-
-
0
-
Net loss
-22,864
-8,057
-31,860
-15,446
Comprehensive loss
-22,864
-8,057
-31,860
-15,446
Basic EPS
-0.18
-0.07
-0.261
-0.14
Diluted EPS
-0.18
-0.07
-0.261
-0.14
Basic Average Shares
124,994,165
122,609,995
122,297,984
110,584,371
Diluted Average Shares
124,994,165
122,609,995
122,297,984
110,584,371
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Comprehensive loss-$22,864K (-68.76%↓ Y/Y)Net loss-$22,864K (-68.76%↓ Y/Y)Net loss beforeincome taxes-$22,864K (-68.76%↓ Y/Y)Interest income and otherincome, net$882K (-57.92%↓ Y/Y)Manufacture And SupplyRevenue$11,911K (24.29%↑ Y/Y)License And RoyaltyRevenue$1,326K (58.05%↑ Y/Y)Co Development AndResearch Fees$582K (53.97%↑ Y/Y)Loss onextinguishment of debt-$11,683K Loss from operations-$8,223K (27.67%↑ Y/Y)Interest expense$2,807K (0.93%↑ Y/Y)Interest expense relatedto royalty...$972K (-32.22%↓ Y/Y)Revenues$13,819K (38.15%↑ Y/Y)Interest expense relatedto the sale of...$61K (0.00%↑ Y/Y)Total costs andexpenses$22,042K (3.14%↑ Y/Y)Selling, general andadministrative$14,063K (10.69%↑ Y/Y)Manufacture and supply$4,017K (-11.93%↓ Y/Y)Research and development$3,962K (-3.48%↓ Y/Y)

Aquestive Therapeutics, Inc. (AQST)

Aquestive Therapeutics, Inc. (AQST)